Recent Finacing
Recent Raise
Abivax develops Obefazimod for ulcerative colitis, completed a 1,275‑patient phase 3 across 36 countries, plans 44‑week maintenance trials and regulatory filings, and is scaling manufacturing with Seqens and Delpharm.
Focus Areas
Total Raised
Funding round
